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Abstract
Background: There is mounting evidence that people with severe mental illness have unhealthy lifestyles, high
rates of cardiovascular and metabolic diseases, and greater risk of early mortality. This study aimed to assess the
cost-effectiveness of a health promotion intervention seeking to improve physical health and reduce substance use
in people with psychosis.
Methods: Participants with a psychotic disorder, aged 18-65 years old and registered on an enhanced care
approach programme or equivalent were recruited from community mental health teams in six mental
health trusts in England. Participants were randomisation to either standard community mental health team
care (treatment as usual) or treatment as usual with an integrated health promotion intervention (IMPaCT).
Cost-effectiveness and cost-utility analyses from health and social care and societal perspectives were
conducted alongside a cluster randomised controlled trial. Total health and social care costs and total
societal costs at 12 and 15 months were calculated as well as cost-effectiveness (incremental cost-
effectiveness ratios and cost-effectiveness acceptability curves) at 15 months based on quality of life (SF-36
mental and physical health components, primary outcome measures) and quality adjusted life years (QALYs)
using two measures, EQ-5D-3 L and SF-36. Data were analysed using bootstrapped regressions with
covariates for relevant baseline variables.
(Continued on next page)
* Correspondence: anitapatelconsulting@gmail.com
†Equal contributors
2Centre for Primary Care and Public Health, Blizard Institute, Barts and The
London School of Medicine and Dentistry, Queen Mary University of London,
Yvonne Carter Building, 58 Turner Street, London E1 2AB, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Heslin et al. BMC Psychiatry  (2017) 17:407 
DOI 10.1186/s12888-017-1570-1
(Continued from previous page)
Results: At 12-15 months 301 participants had full data needed to be included in the economic evaluation.
There were no differences in adjusted health and social care costs (£95, 95% CI -£1410 to £1599) or societal
costs (£675, 95% CI -£1039 to £2388) between the intervention and control arms. Similarly, there were no
differences between the groups in the SF-36 mental component (−0.80, 95% CI -3.66 to 2.06), SF-36
physical component (−0.68, 95% CI -3.01 to 1.65), QALYs estimated from the SF-36 (−0.00, −0.01 to 0.00) or
QALYs estimated from the EQ-5D-3 L (0.00, 95% CI -0.01 to 0.02).
Cost-effectiveness acceptability curves for all four outcomes and from both cost perspectives indicate that
the probability of the health promotion intervention being cost-effective does not exceed 0.4 for
willingness to pay thresholds ranging from £0-£50,000.
Conclusions: Alongside no evidence of additional quality of life/clinical benefit, there is also no evidence
of cost-effectiveness.
Trial registration: ISRCTN58667926. Date retrospectively registered: 23/04/2010. Recruitment start date: 01/03/2010.
Keywords: Health promotion, Psychosis, Quality of life, Economic, Cost
Background
There is mounting evidence that people with severe
mental illness have unhealthy lifestyles [1–4], high rates
of cardiovascular and metabolic diseases [5], and greater
risk of early mortality [6, 7]. These major health implica-
tions inevitably carry substantial economic conse-
quences, both within and outside of the health system
[8]. There is an urgent need to address modifiable life-
style factors to reduce cardiovascular and other diseases
associated with morbidity and mortality [2, 4, 9, 10].
There is a particularly urgent need locally, with the
levels of cardiometabolic abnormalities in South London
[11] among the highest reported in the world [5]. One
promising way to achieve this is through increasing staff
awareness of their role in achieving this [12].
We developed a new health promotion intervention
(HPI) designed to be integrated into routine clinical care
and implemented by the patient’s usual care coordinator
– the main clinical contact (from one of a number of
professional backgrounds) for patients with psychosis
receiving secondary mental health services in the UK.
We present here the findings from an economic evalu-
ation of this intervention within a cluster randomised
controlled trial. To our knowledge there are no other
economic evaluations of integrated health promotion
interventions for people with psychosis. Economic evalu-
ations of specific, separate interventions [13, 14] suggest
greater costs associated with achieving outcome
improvements, rather than any clear economic advan-
tages. Thus there remains a need for cost-effective
approaches to addressing this issue.
Methods
Design and intervention
Full details of the pragmatic multi-centre phase III two-
arm cluster RCT trial and findings from its effectiveness
study have been described elsewhere [15–17]. Briefly,
community care coordinators with a minimum of four
patients on their caseload in participating community
mental health teams (CMHTs) were approached in a
random sequence and invited to participate. After gaining
their informed consent to participate, we approached
patients on their caseload meeting the inclusion criteria
(18-65 years old with a diagnosis of psychotic disorder
(ICD-10 F20-29, F31.2, F32.3, F33.3) under the care of a
Community Mental Health Team (CMHT) registered on
an enhanced level of the Care Approach Programme (CPA)
or equivalent). Exclusion criteria are described elsewhere
[15] and we did not recruit from first episode services.
After completing baseline assessments on all con-
senting patients in a care co-ordinator’s caseload, care
coordinators were randomised, stratified by borough,
using randomisation blocks of random sizes to deliver
either treatment as usual (TAU) with an integrated
9 month intensive HPI (IMPaCT therapy) or treat-
ment as usual alone. All care coordinators were pro-
vided a one-off information session on mental and
physical health issues. All outcome assessments were
undertaken by researchers blind to treatment alloca-
tion. It was hypothesised that the intervention arm
would have better quality of life and health outcomes
at 12 month follow-up, and that this would be
sustained 3 months after completion of the formal
intervention, at 15-months follow up.
The economic evaluation was integrated into the trial
and was based on primary data collection within the
trial. It focused on costs at 15 months (for the previous
3 months) from two perspectives: health and social care;
and societal.
Ethical approval was obtained from the joint South
London and Maudsley and the Institute of Psychiatry
NHS Ethics Committed (REC Ref no 09/HO80/41).
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Data collection
An adapted version of the Client Service Receipt Inven-
tory (CSRI) [18] was used to measure individual-level
resource use. It covered the use of (all-cause) secondary
and community-based health and social care services,
prescription medication, time off work, and key social
security benefits received by participants and carers. It
was administered as a retrospective self-report
questionnaire-based interview conducted by assessors
blind to treatment allocation. It covered the previous 6-
month period at baseline and 12 month follow-up, and
the previous 3-month period at 15 month follow-up. Data
related to delivery of the intervention were recorded by
care coordinators using specifically designed proformas.
Unit costs
Unit costs (see online supplementary material) were
applied to individual-level resource use data to calculate
total costs. Briefly, unit costs for most hospital and
primary care services were obtained from the NHS
Reference Costs [19] (inflated to 2011-12 prices using the
Hospital and Community Health Services Pay and Prices
Index or Retail price index as appropriate [20]) and the
Unit Costs of Health and Social Care [20]. Medication
unit costs, taken from the British National Formulary [21]
were converted into cost per milligram (mg) based on the
most cost-efficient pack size, choosing maintenance doses
over initial treatment doses and generic formulations over
branded ones to obtain conservative estimates. Lost prod-
uctivity costs were estimated by applying national average
wage rates to lost work days (human capital approach)
and were capped at 5 days per week.
The cost of the intervention is described in full else-
where [17]. Briefly, the intervention consisted of four
components and we estimated costs for each of these:
production of manuals (excluding the development
work); training care coordinators; ongoing supervision of
care coordinators; and implementation of the interven-
tion by care coordinators to trial participants. The mean
cost of the IMPaCT intervention was £226.40. The com-
parable cost for patients in the TAU arm was £3.52 in
relation to the one-off information session provided to
all care coordinators.
All costs are reported in pounds sterling (£) at 2011-12
prices. Costs related to the intervention were not
discounted since they were incurred within the first year.
However, all other costs (and outcomes) related to the 12-
15 month assessment period were discounted using a rate
of 3.5% [22].
Outcomes
All outcome measures were administered as interviewer-
administered self-report questionnaires at baseline, 12
and 15 month follow-ups. Cost-effectiveness analyses
were based on the joint primary outcome measures, the
SF-36 mental component score and SF-36 physical
component score [23]. Cost-utility analyses were based
on QALYs derived from the SF-36 (US version 1) via the
SF-6D and the EQ-5D-3 L [24]. Appropriate utility
weights were attached to health states for each measure
at baseline, 12 and 15 months [25, 26]. QALY gains
between 12 months and 15 months were then calculated
using the total area under the curve approach with linear
interpolation between assessment points [27].
Analyses
Data were analysed using Stata (version 11) [28]. Partici-
pants were analysed according to the group to which
they were randomised regardless of intervention compli-
ance. No normalisation was used, and outliers were not
adjusted or removed.
Costs and outcomes were compared at baseline, 12
and 15 months and are presented as mean values by arm
with standard deviations. Mean differences and 95%
confidence intervals (CIs) were obtained by non-
parametric bootstrap regressions (ordinary least squares
(OLS), 1000 repetitions) to account for the non-normal
distribution commonly found in economic data, with ad-
justment for clustering at the care coordinator level. To
provide more relevant treatment-effect estimates [29]
(OLS) regressions to calculate mean differences in costs
at 12 and 15 months included covariates for the baseline
value for the same cost category, baseline SF-36 mental
component score, baseline SF-36 physical component
score, baseline SF-36 utility and baseline EQ-5D-3 L
utility, plus baseline demographic variables expected to
be associated with costs (gender, ethnicity, borough).
Similarly, comparisons of outcome data included covari-
ates for baseline: SF-36 mental component score, SF-36
physical component score, SF-36 utility and EQ-5D-3 L
utility, plus baseline demographic variables expected to
be associated with outcome (gender, age, ethnicity, place
of birth and borough).
Individual item non-response for the CSRI was min-
imal given the interview approach taken. Where it
occurred, an item cost was imputed using the mean cost
for the same item for other users in the same trial arm
and at the same assessment point. Where this was not
possible, the overall cost component was imputed using
the mean cost for the same cost component in the same
trial arm at the same assessment point. For medication
data, a series of assumptions and imputations were
necessary depending on the nature of the missing
information, as follows, making use of available data
components where possible. If medication name was
missing, we applied an average prescription cost (from
Department of Health prescription cost analysis (PCA)),
accounting for the reported number of days on that
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medication, and assuming the prescription lasted for 1
month. If number of days on medication was missing, a
PCA average item cost for that medication was used,
with the assumption that the patient was prescribed that
medication just once in that period. If dose was missing,
a PCA average item cost was used, assuming each
prescription lasted 1 month but accounting for number
of days on the medication. If the dose unit was missing,
a PCA average item cost was used assuming each
prescription lasted 1 month, with an account of the num-
ber of days on medication. If dose frequency was missing,
a PCA average item cost was used, assuming each pre-
scription lasted 1 month, again accounting for number of
days. Finally, if it was unknown whether the medication
was administered as a depot, a PCA average item cost was
used assuming each prescription lasted 1 month, account-
ing for the number of days on medication.
The base case analysis was undertaken using cases
with available relevant cost and/or outcome data (i.e.
excluding those lost to follow-up for the CSRI, EQ-5D-
3 L or SF-36 assessments as relevant).
The economic evaluation takes a decision-making
approach which ignores statistical significance (of both
the clinical and economic outcomes) and instead
focusses on the probability of one intervention being
cost-effective compared to another in light of the avail-
able data. This is the approach recommended over trad-
itional reliance on decision rules regarding statistical
significance [30, 31]. Cost-effectiveness and cost-utility
analyses were conducted at 15 months to focus on the
more pertinent question of whether any effect lasted
beyond the end of the intervention, but 12 month cost
and outcome data are also reported for information. The
economic evaluation examined 8 possible cost-outcome
combinations (accounting for the two cost perspectives
and four outcomes). Incremental cost-effectiveness
ratios (ICERs) were calculated for any combination
showing both higher costs and better outcomes in either
the intervention group or control group (it is unneces-
sary to calculate ICERs for any combinations where one
group shows both lower costs and better outcomes as it
is then considered to ‘dominate’ the other group).
Uncertainty around cost-effectiveness/cost-utility was
explored using cost-effectiveness planes and cost-
effectiveness acceptability curves (CEACs) based on the
net-benefit approach [32]. These curves are an alterna-
tive to confidence intervals around ICERs and show the
probability that one intervention is cost-effective com-
pared to the other, for a range of values that a decision
maker would be willing to pay for an additional unit of
an outcome. Net benefits for each participant were
calculated using the following formula, where λ is the
willingness to pay for one additional unit of outcome:
Net benefit = (λ x outcome) - cost.
A series of net benefits were calculated for each individ-
ual for a λ range that would include any policy-making
perspectives relevant at the time of analysis. After calculat-
ing net benefits for each participant for each value of λ,
coefficients of differences in net benefits between the trial
arms were obtained through a series of bootstrapped
linear regressions (1000 repetitions) of group upon net
benefit which included the same covariates used for the
comparisons of mean costs and outcomes (i.e. baseline
value of: the same cost category, SF-36 mental component
score; SF-36 physical component score; EQ-5D-3 L utility
score; SF-36 utility score; gender; age; ethnicity; place of
birth; borough) and an adjustment for clustering by care
coordinator. The resulting coefficients were then
examined to calculate for each value of λ the proportion
of times that the intervention group had a greater net
benefit than the control group. These proportions were
then plotted to generate CEACs for all eight cost-outcome
combinations.
Although the intervention was conducted for
9 months, cost-effective analyses were conducted on the
12-15 month data. This was done for two reasons.
Firstly, to allow a broad enough time window to conduct
outcome assessments, which was necessary due to the
data collection approach needed here. Secondly, a 9-
month assessment could misrepresent cost-effectiveness
of the intervention if any outcome improvements or cost
savings were subsequently not sustained even for
3 months.
Sensitivity analyses
We conducted four sensitivity analyses to check the
robustness of the base case analyses defined above. First,
we explored the potential impact of excluding those lost
to follow-up. We examined key socio-demographic and
clinical characteristics for those included and excluded
from the analyses and conducted an intention to treat
(ITT) analysis which included those lost to follow-up by
imputing missing total costs and outcomes using imput-
ation in STATA [28]. Imputations of costs and outcomes
were based on variables which were expected to be asso-
ciated with costs and outcomes. For cost imputations,
these variables were baseline and 12 month values for
the: equivalent cost category; SF-36 mental component
score; SF-36 physical component score; EQ-5D-3 L
utility score; SF-36 utility score; plus gender, ethnicity,
borough, age, place of birth and care coordinator.
Imputation of outcomes was based on baseline and
12 month values of the: SF-36 mental component score;
SF-36 physical component score; EQ-5D-3 L utility
score; SF-36 utility score; plus gender, age, ethnicity, age,
place of birth and borough, and care coordinator.
Secondly, to explore the potential impact of having
follow-up interviews conducted outside of the planned
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assessment window (more than 30 days before or after
the follow-up date), we conducted a ‘correct time
window’ analysis including only those trial participants
whose data were collected within the correct window.
Thirdly, to explore the potential impact of insufficient
implementation of the IMPaCT Therapy, we conducted
a per protocol analysis which included only those inter-
vention arm participants who received the pre-defined
minimum of six intervention sessions of at least 30 min
duration each. Finally, to explore the potential impact of
care coordinator drop out, we conducted analyses which
included only those participants whose care coordinator
remained the same throughout the study.
For each of these sensitivity analyses, we examined
whether conclusions concerning the mean difference in
costs or outcomes between the two trial arms differed to
those drawn from the base case analyses.
Patient and public involvement
Service users and carers, with lived experience were
involved throughout the study, from applying to funding to
managing the steering group, to co-authoring this paper.
Focus groups were also run with service users to refine our
approach. Additionally a delphi process with service users
was used to develop the health promotion intervention.
Results
One hundred four care coordinators were recruited and
randomized. Four hundred six patients from randomized
care coordinators were eligible and consented for the
trial. Fifty two care coordinators with 213 patients were
randomized to the IMPaCT Therapy and 52 care coordi-
nators with 193 patients were randomized to TAU.
Responses rates for the client service receipt inventory
were 100% (n405), 79% (n319) and 74% (n301) at base-
line, 12 months and 15 months respectively and similar
between the intervention and control group. Corre-
sponding response rates for the SF-36 were 99% (n402),
77% (n313) and 73% (n297), and for the EQ-5D-3 L were
100% (n404), 78% (n315) and 74% (n301). All partici-
pants had full data on intervention use. There were no
notable differences in the baseline characteristics of the
sub-samples included in the base case analyses of those
with available data against the full sample.
Resource use
Resource use patterns at 12 and 15 months are
described in Tables 1 and 2. These were not compared
statistically since the economic evaluation was focused
on costs and cost-effectiveness/utility, and to avoid prob-
lems associated with multiple testing. The data suggest
that both arms were broadly balanced in their use of
core services both before and during the study. As
would be expected for this group of patients, service use
is very broad in both nature and sector, illustrating the
complexity of their care provision.
Costs and outcomes
We present total costs from the two cost perspectives
and sub-totals for the components within these (gener-
ally by sector) (Table 3). There were no differences in
these sub-totals by trial arm, except that the cost of the
intervention was naturally higher in the intervention
group given the additional inputs required compared
with the control group (adjusted mean difference £311,
95% CI £267 to £355) and costs borne by charities were
higher in the intervention group at 12 months (adjusted
mean difference £80, 95% CI £9 to £151). Health and
social care and lost productivity formed the largest
components of total societal costs.
Comparisons of total costs from both health and social
care and societal perspectives at 15 months suggested no
difference between the trial arms although the 95% con-
fidence intervals suggest a tendency for societal costs to
be greater in the intervention arm (Table 3). All sensitiv-
ity analyses confirmed this conclusion.
There were no differences in outcome at any of the
assessments (Table 4). As with cost data, all sensitivity
analyses confirmed this conclusion.
Cost-effectiveness
From a health and social care perspective, the probability
of the IMPaCT Therapy being cost-effective does not
exceed 0.4 for any of the examined willingness to pay
thresholds for QALY gains (based on either the SF-36 or
EQ-5D-3 L) or for the physical and mental component
scores gains (Fig. 1). Similarly, the probability of cost-
effectiveness from a societal perspective does not exceed
0.2 (Fig. 1).
Discussion
We found no evidence of a clear difference in health and
social care or societal costs between the two trial arms,
in quality of life outcomes or cost-effectiveness as a
result of delivering a comprehensive and integrated
health promotion intervention to people with established
psychosis. The corresponding outcome evaluation
discusses the many possible explanations for lack of out-
come effect and the same factors will likely have
impacted on costs and cost-effectiveness since a signifi-
cant factor was lack of successful implementation of the
IMPaCT Therapy. Briefly, they include policy and prac-
tice steps towards greater parity between mental and
physical health care which took place during the study
may have improved the health of both groups, staff
turn-over meant a sizable proportion of participants did
not receive the intervention, and care co-ordinators
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Table 1 Resource use at 12 month follow-up (for the previous 6 months)
Intervention (n = 160) Controls (n = 159)
Resource Unit Number of users Mean contactsa SD Number of users Mean contactsa SD
Specialist accommodation
Supported housing / assisted living bed day 37 182 1 30 179 12
Sheltered housing bed day 1 182 – 6 158 60
Hostel / shelter bed day 4 182 0 5 152 68
Hospital inpatient
Inpatient bed day 42 182 1 41 173 34
Hospital outpatient
Psychiatric outpatient visit 13 4 2 6 2 1
Non-psychiatric / general / medical outpatient visit 14 3 2 16 2 2
Diabetes clinic visit 11 3 3 9 1 1
Blood tests visit 79 5 4 69 4 3
Psychiatric day hospital visit 2 2 1 1 6 –
Non-psychiatric / general / medical day hospital visit 2 1 0 2 4 4
Day surgery centre visit 4 2 1 6 1 0
A&E department visit 22 2 4 19 2 1
X-ray visit 23 1 1 14 1 <1
Substance misuse clinic visit 3 10 12 3 7 4
Dietetics visit 4 2 3 1 1 –
Community based day services
Community based services visit 70 44 40 63 40 36
Community based professionals
Care coordinator surgery visit 95 9 7 98 7 7
Care coordinator home visit 67 9 8 64 8 8
Care coordinator phone call 32 8 10 29 6 7
Home treatment team surgery visit 1 1 – 1 1 –
Home treatment team home visit 10 17 11 3 13 7
Home treatment team phone call 1 2 – 0 – –
Crisis resolution team surgery visit 1 3 – 0 – –
Crisis resolution team home visit 1 2 – 0 – –
Crisis resolution team phone call 1 2 – 0 – –
Community psychiatric nurse surgery visit 1 6 – 2 4 4
Community psychiatric nurse home visit 2 5 2 3 3 3
Social worker surgery visit 4 3 3 5 2 1
Social worker home visit 2 9 4 2 3 2
Psychiatrist surgery visit 85 2 2 86 2 4
Psychiatrist home visit 7 5 9 8 6 8
Psychologist surgery visit 10 11 10 15 11 13
Psychologist home visit 1 14 – 1 24 –
Psychologist phone call 0 – – 1 1 –
Psychotherapist surgery visit 1 4 – 1 3 –
Counsellor surgery visit 9 4 5 5 4 2
GP surgery visit 110 3 3 104 3 4
GP home visit 1 3 – 2 3 2
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implementing the intervention struggled to deliver the
minimum dose.
Strengths and limitations of the study
This study was a pragmatic trial based in five NHS men-
tal health trusts. The intervention was specifically
designed to be accessible to as many people as possible
by being delivered by care coordinators as part as care
as usual rather than requiring people to attend add-on
or group appointments. However, there were also some
methodological limitations. Data on resource use were
collected by self-report. This makes it subject to partici-
pant recall bias. However, the approach was necessary in
relation to strengths of the study design – our interest in
the full range of formal services used by this group,
given the mental and physical health focus here, and also
in broader societal costs which are of particular rele-
vance for a patient group whose health and care needs
can have economic impacts upon multiple sectors of
society. Even a narrower cost perspective would have
been hindered by a lack of integration of relevant health
and social care sector client records and a possible lack
of comparability in record systems for all study sites.
There is though evidence for the reliability of the self-
report approach in similar populations [33, 34] and there
is no reason to believe that any biases related to data
collection would be imbalanced between the two trial
arms, particularly since the CSRI was administered by
blinded assessors.
A further limitation is we may have double-counted
resource use associated with the IMPaCT Therapy. We
collected this information separately from care coordina-
tors, rather than from patient participants, to avoid
unblinding the assessors conducting the participant
interviews. Patients would anyway have found it difficult
to separately report care related to the IMPaCT Therapy
since it was designed to be integrated into usual care.
However, this inevitably means that patient reports of
contacts with their care coordinator include inputs asso-
ciated with the intervention. While this may double-
count absolute estimates of costs for the intervention
arm, this would result in over-estimation and thus bias
against, rather than for, the intervention arm.
There has been some discussion around the validity of
the SF-36 and EQ-5D-3 L among study participants with
mental health problems, especially those with schizo-
phrenia and other psychoses [35]. Although the two
measures are commonly used, and indeed recom-
mended, for economic evaluation to inform policy-
making in England, Brazier et al. [35] suggest that
neither scale performs particularly well in these particu-
lar patient groups in terms of quantitative testing against
Table 1 Resource use at 12 month follow-up (for the previous 6 months) (Continued)
Intervention (n = 160) Controls (n = 159)
Resource Unit Number of users Mean contactsa SD Number of users Mean contactsa SD
GP phone call 1 1 – 1 1 –
Blood test at GP surgery visit 38 2 1 44 2 2
Diabetes nurse surgery visit 9 2 4 6 2 1
Diabetes nurse phone call 0 – – 3 1 0
Practice nurse surgery visit 33 3 3 21 11 39
Practice nurse home visit 0 – – 1 6 –
Practice nurse phone call 1 2 – 0 – –
District nurse surgery visit 2 6 6 0 – –
Occupational therapist surgery visit 4 6 7 2 6 4
Occupational therapist home visit 4 22 34 2 3 0
Occupational therapist phone call 1 2 – 1 2 –
Dietician surgery visit 3 1 0 6 3 3
Home help home visit 11 53 52 7 61 59
Meals on wheels home visit 2 13 16 0 – –
Pharmacist for advice surgery visit 16 2 2 14 3 2
Pharmacist for advice phone call 2 1 0 0 – –
NHS direct phone call 0 – – 2 2 1
Samaritans phone call 5 79 90 4 24 45
Medication 159 – – 158 – –
aMean for users only
All quantities are rounded to nearest whole number
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Table 2 Resource use at 15 month follow-up (for the previous 3 months)
Intervention (n = 152) Controls (n = 149)
Resource Unit Number of users Mean contactsa SD Number of users Mean contactsa SD
Specialist accommodation
Supported housing / assisted living bed day 36 90 3 30 90 3
Sheltered housing bed day 2 70 30 6 91 0
Hostel / shelter bed day 1 81 – 5 91 0
Hospital inpatient
Inpatient bed day 39 90 8 41 90 2
Hospital outpatient
Psychiatric outpatient visit 8 2 1 1 1 –
Non-psychiatric / general / medical outpatient visit 7 1 <1 10 2 2
Diabetes clinic visit 4 1 0 6 1 0
Blood tests visit 63 2 2 56 3 1
Psychiatric day hospital visit 2 5 1 0 – –
Non-psychiatric / general / medical day hospital visit 1 2 – 3 1 0
Day surgery centre visit 3 1 0 2 1 0
A&E department visit 15 1 1 15 1 1
X-ray visit 10 1 0 12 1 1
Substance misuse clinic visit 2 24 17 1 1 –
Dietetics visit 2 1 0 2 1 0
Community based day services
Community based services visit 57 20 19 50 26 25
Community based professionals
Care coordinator surgery visit 78 5 6 70 4 4
Care coordinator home visit 59 5 3 52 4 3
Care coordinator phone call 28 5 6 26 5 5
Home treatment team surgery visit 2 2 1 1 8 –
Home treatment team home visit 7 9 8 4 12 13
Crisis resolution team surgery visit 1 1 – 0 – –
Crisis resolution team home visit 1 1 – 1 1 –
Early intervention team surgery visit 1 36 – 0 – –
Community psychiatric nurse surgery visit 6 6 4 13 4 2
Community psychiatric nurse home visit 2 4 1 3 1 1
Community psychiatric nurse phone call 3 8 10 4 5 5
Social worker surgery visit 2 8 6 4 5 5
Social worker home visit 0 – – 2 7 7
Social worker phone call 0 – – 1 5 –
Psychiatrist surgery visit 65 1 1 60 1 1
Psychiatrist home visit 3 5 6 5 4 5
Psychologist surgery visit 14 6 5 8 5 5
Psychologist home visit 1 10 – 0 – –
Psychotherapist surgery visit 2 10 3 0 – –
Psychotherapist home visit 0 – – 1 1 –
Counsellor surgery visit 3 2 2 1 2 –
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psychometric criteria and that both have a limited cover-
age of domains identified as relevant by people with
mental health problems. Thus, it is unclear whether the
lack of QALY difference between the two trial arms
reflects a lack of intervention effect or limitations associ-
ated with the measurement properties of these two
health-related quality of life measures. However, given
the lack of effect based on the SF-36 mental and physical
component scores, and all other outcome measures, it is
unlikely that there was a difference in QALYs that we
have been unable to detect.
Although the intervention was conducted for 9 months,
cost-effective analyses were conducted on the 12-15 month
data. There could have been larger cost and outcome dif-
ferences at 9 months (the end of intervention) which
reduced over time thus no significant differences were
seen at 12 and 15 months. However, this ensures the cost-
effectiveness of the intervention could not be misrepre-
sented if any outcome improvements or cost savings were
subsequently not sustained even for 3 months.
Finally, the time horizon of the evaluation is likely to
have been insufficient to identify all relevant outcomes for
this patient group, particularly given the longer term
nature of the impacts of physical health problems. However,
it is unlikely that any effects of the intervention would tran-
spire in the longer term if absent in the short term.
We used the human capital approach to valuing prod-
uctivity loss rather than the friction cost method. While
the human capital approach may over-estimate absolute
values for lost productivity, such over-estimation will
only impact the findings of the economic evaluation if
productivity outcomes are different between the control
and intervention groups, which does not appear to be
the case here. Further, results from a societal perspec-
tive, which includes productivity losses, is consistent
with results from a health and social care perspective.
Comparison with previous research
While a number of studies have demonstrated effect-
iveness of interventions to address lifestyle factors in
similar patient groups [35–38] few include an eco-
nomic evaluation.
Verhaeghe et al. [13] investigated the cost-
effectiveness of a health promotion targeting physical
Table 2 Resource use at 15 month follow-up (for the previous 3 months) (Continued)
Intervention (n = 152) Controls (n = 149)
Resource Unit Number of users Mean contactsa SD Number of users Mean contactsa SD
GP surgery visit 81 3 2 83 2 1
GP home visit 1 1 – 0 – –
GP phone call 1 2 – 1 4 –
Blood test at GP surgery visit 26 2 5 27 1 1
Diabetes nurse surgery visit 4 2 2 3 1 1
Diabetes nurse home visit 1 1 – 0 – –
Practice nurse surgery visit 16 2 2 21 2 1
Practice nurse phone call 1 1 – 0 – –
District nurse surgery visit 3 21 34 2 46 62
District nurse home visit 1 24 – 0 – –
Occupational therapist surgery visit 4 12 9 5 5 4
Occupational therapist home visit 2 13 16 3 12 0
Occupational therapist phone call 1 3 – 0 – –
Dietician surgery visit 1 1 – 6 2 1
Dietician home visit 0 – – 1 12 –
Home help home visit 12 38 52 4 39 37
Meals on wheels home visit 4 47 33 1 15 –
Pharmacist for advice surgery visit 6 3 2 8 3 4
Pharmacist for advice phone call 2 2 1 1 1 –
NHS direct phone call 2 7 8 5 3 5
Samaritans phone call 4 36 39 4 15 21
Medication 149 145
aMean for users only
All quantities are rounded to nearest whole number
Heslin et al. BMC Psychiatry  (2017) 17:407 Page 9 of 13
activity and healthy eating in people with mental illness
using a Markov decision model. The intervention con-
sisted of 10 weeks of psycho-educational and behav-
ioural group-based sessions, group based exercise
(weekly 30 min supervised walking sessions), and indi-
vidual support from the mental health nurses. The au-
thors reported an incremental cost-effectiveness ratio of
Euro 27,096 per QALY in men and Euro 40,139 per
QALY in women although this was very sensitive to
modelling assumptions.
Meenan et al. [14] reported on a randomised
controlled trial and economic evaluation of a lifestyle
intervention designed to reduce weight among
individuals with serious mental illnesses who were
taking antipsychotic medications. The authors
reported no significant change in EQ-5D scores but
reported ICERs between $1623 to $2527 per
kilogram reduced depending on which costs were
included and which cohort of patients were included
(completers versus intention to treat). The authors
also reported ICERs from $467 to $727 per mg/dL
reduced (fasting glucose) depending on which costs
and cohort were used.
Both these studies thus suggest greater costs associ-
ated with intervening to produce improved outcomes in
this population.
Table 3 Costs at baseline, 12 and 15 months (2011/12 prices, all 15 month costs, except the intervention costs, are discounted)
Intervention
n = 213
Control
n = 193
Unadjusted
mean differenced
95% CId Adjusted mean
differencee
95% CIe
valid
n
Mean
£
SD valid
n
Mean
£
SD
Component Costs at Baseline
Health & social care excluding
interventionb
212 10,242 13,374 193 9714 13,767 528 −2953 to 4010 967 −2442 to 4435
Charityb 212 83 611 193 80 435 3 −109 to 115 −22 −137 to 94
Lost productivityb 212 8755 5964 193 7472 6311 1283 −354 to 2920 456 −894 to 1806
Patientb 212 72 433 193 188 188 35 −31 to 102 33 −37 to 104
Benefitsb 212 2211 1006 193 2009 940 202a 13 to 391a 127 −70 to 324
Component Costs at 12 month
Health & social care excluding
interventionb
160 10,220 12,341 159 10,196 16,987 24 −4219 to 4267 −1596 −5145 to 1954
Charityb 160 120 369 159 61 256 60 −6 to 125 80a 9 to 151a
Lost productivityb 160 8882 5998 159 7707 6333 1174 −317 to 2665 1038 −367 to 2443
Patientb 160 84 369 159 53 300 31 −38 to 100 25 −46 to 96
Benefitb 160 2328 931 159 2129 957 200 −14 to 413 87 −105 to 279
Component Costs at 15 month
Health & social care excluding
interventionc
152 4874 6317 149 4708 6383 166 −1577 to 1910 −231 −1734 to 1272
Charityc 152 63 215 149 49 230 14 −39 to 67 24 −37 to 84
Lost productivityc 152 4731 2674 149 3880 3027 850a 127 to 1573a 608 −25 to 1240
Patientc 152 24 141 149 30 162 −6 −38 to 27 −6 −37 to 25
Benefitsc 152 1089 439 149 1049 441 40 −70 to 150 −24 −125 to 76
Intervention 213 316 173 193 4 0 312a 267 to 357a 3142a 268 to 359a
Total Costs at 15 months
Health & social care including
interventionf
152 5209 6326 149 4711 6383 498 −1248 to 2244 95 −1410 to 1599
Societal perspective including
interventionf
152 11,116 7271 149 9720 7707 1396 −684 to 3476 675 −1039 to 2388
All figures are rounded to nearest whole number
aConfidence interval excludes zero
bCosts for a 6 month retrospective period
cCosts for a 3 month retrospective period
dAdjusting for clustering of care coordinator only
eIncludes covariates for baseline: equivalent cost, SF-36 mental component score, SF-36 physical component score, EQ-5D-3 L utility, SF-36 utility, gender, ethnicity
and borough, plus clustering for care coordinator
fFifteen month costs discounted
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Implications for policy
As reported by Gaughran et al. [16] a health promo-
tion intervention targeting multiple risk factors has
proved difficult to integrate into usual care for many
contextual and pragmatic reasons. This leaves an
unaddressed care gap that carries significant implica-
tions for both patient health and economic costs.
An RCT of a similar intervention from Denmark,
likewise failed to show a clinically significant effect
[39]. Other studies show promise that interventions
targeting specific issues [36, 38, 40] may be simpler
to implement or more effective in improving phys-
ical outcomes. It would be vital to assess the
resource and cost-effectiveness implications of such
models since add-on services would present
additional care costs in the short-term. Current
financial pressures in the NHS mental health care
suggest challenges in delivering new services
whether through new funding or reallocation of
existing budgets - hence our attempt to develop an
intervention that can be provided pragmatically
within existing patient contacts.
Table 4 Outcomes at baseline, 12 and 15 months (all 15 month outcomes discounted)
Intervention
n = 213
Control
n = 193
Unadjusted mean
differenceb
95% CIb Adjusted mean
differencec
95% CIc
valid n Mean SD valid n Mean SD
Baseline
SF-36 mental component score 213 41.37 13.26 193 42.25 11.81 −0.88 −3.44 to 1.68 −0.26 −1.55 to 1.02
SF-36 physical component score 213 45.83 10.94 193 47.04 9.26 −1.20 −3.31 to 0.91 −0.60 −1.72 to 0.52
SF-36 utility 210 0.69 0.16 192 0.71 0.14 −0.02 −0.05 to 0.02 0.00 −0.01 to 0.01
EQ-5D-3 L utility 211 0.76 0.31 193 0.79 0.28 −0.02 −0.08 to 0.04 0.01 −0.04 to 0.06
12 months
SF-36 mental component score 160 43.18 13.31 158 44.09 13.47 −0.91 −3.94 to 2.11 −0.05 −2.64 to 2.55
SF-36 physical component score 160 46.76 11.23 158 49.02 10.55 −2.27 −4.74 to 0.21 −1.45 −3.56 to 0.66
SF-36 utility 158 0.70 0.16 155 0.71 0.15 −0.02 −0.05 to 0.02 −0.00 −0.03 to 0.02
EQ-5D-3 L utility 159 0.80 0.25 156 0.80 0.28 0.00 −0.06 to 0.06 0.03 −0.03 to 0.08
15 months
SF-36 mental component score 152 42.47 13.58 149 45.01 13.65 −2.54 −6.00 to 0.92 −0.80 −3.66 to 2.06
SF-36 physical component score 152 47.25 11.62 149 48.54 9.88 −1.29 −4.02 to 1.44 −0.68 −3.01 to 1.65
SF-36 utility 149 0.66 0.14 148 0.70 0.15 −0.03a −0.07 to −0.00a −0.02 −0.05 to 0.01
SF-36 based QALY gain 134 0.17 0.03 139 0.17 0.09 −0.01 −0.01 to 0.00 −0.00 −0.01 to 0.00
EQ-5D-3 L utility 152 0.77 0.24 149 0.80 0.25 −0.02 −0.09 to 0.04 0.00 −0.06 to 0.06
EQ-5D-3 L based QALY gain 137 0.19 0.05 140 0.20 0.06 −0.00 −0.02 to 0.01 0.00 −0.01 to 0.02
aConfidence interval excludes zero
bAdjusting for clustering of care coordinator
cIncludes covariates for baseline: SF-36 mental component score, SF-36 physical component score, EQ-5D-3 L utility, SF-36 utility, gender, age, ethnicity, place of
birth and borough, plus clustering for care coordinator
Fig. 1 Cost-effectiveness acceptability curves for SF-36 physical and mental component scores plus SF-36 and EQ-5D-3 L based QALYs from a
health & social care perspective and societal perspective
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Conclusions
We found no evidence that an integrated health promo-
tion intervention for people with established psychosis
improves outcomes or achieves savings in health and
social care or societal costs. Given the long term eco-
nomic implications of increased cardiovascular risk and
premature mortality for this population, it is vital that
other options for early intervention are developed and
assessed for cost-effectiveness is given the multiple pres-
sures on health and social care budgets now and in the
foreseeable future.
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